Trials / Completed
CompletedNCT06489704
High Altitude (HA) Residents With High Altitude Pulmonary Hypertension (HAPH), Pulmonary Artery Pressure (PAP) Assessed at HA (3200 m) vs LA (760 m)
Comparative Study of Pulmonary Artery Pressure (PAP) Assessed by Echocardiography in Patients With High Altitude Pulmonary Hypertension (HAPH) Permanently Residing Above 2500 Meters When Assessed Near Resident High Altitude (HA) at 3200 m vs. at Low Altitude (LA) at 760 m
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To study the effect of relocation from 3200 m (Aksay) to 760 m (Bishkek) in patients with high altitude pulmonary hypertension (HAPH) who permanently live \>2500 m on pulmonary artery pressure (PAP)
Detailed description
This research in highlanders with HAPH diagnosed by echocardiography and defined by a RV/RA \>30 mmHg who permanently live at HA \>2500 m will have pulmonary arterial pressure (PAP) assessed by echocardiography near their living altitude in Aksay at 3200 m and at 760 m in Bishkek the day after the first and the seventh night after relocation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Echocardiography | Echocardiography will be performed according to clinical standards |
Timeline
- Start date
- 2024-07-02
- Primary completion
- 2024-09-27
- Completion
- 2024-09-27
- First posted
- 2024-07-08
- Last updated
- 2026-01-21
Locations
1 site across 1 country: Kyrgyzstan
Source: ClinicalTrials.gov record NCT06489704. Inclusion in this directory is not an endorsement.